Martín-Ramírez R, González-Nicolás MÁ, Álvarez-Tosco K, Machín F, Ávila J, Morales M, Lázaro A, Martín-Vasallo P.Cells....
https://www.mdpi.com/1422-0067/26/16/7927 González-Nicolás MÁ, Humanes B, Herrero R, Arenillas M, López B, Ferruelo A, Lore...
We at Telara Pharma are thrilled to see our partner Arch Biopartners Inc (ARCH:TSXV) (ACHFF:OTCQB) announce the start of patient r...
...
Telara Pharma is proud to announce that it has been officially recognized with the Emerging Company Certification, granted by the...
Our Co-Founder and CSO Dr. Alberto Lázaro has just published a Commentary in the Kidney International Journal, the official journ...
Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI) Cilastatin is parti...
TORONTO, June 27, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and O...
Telara Pharma (Lead coordinator, Madrid, Spain), Fundación para la Investigación Biomédica del Hospital Gregorio Marañón (FIB...
Neotec is a highly competitive programme that aims to foster technology and innovation for the development of companies based in S...